Narcolepsy Type 1 vs Type 2 — cataplexy and CSF orexin-A differentiate the subtypes
Every narcolepsy diagnosis starts with irresistible daytime sleep attacks.
Sudden, irresistible sleep urges strike regardless of prior rest.
Naps are often brief and subjectively refreshing.
EDS alone cannot separate type 1 from type 2 narcolepsy.
Sleep apnea, depression, and shift work also cause EDS.
Objective testing is required before diagnosis proceeds.
MSLT and CSF testing move differentiation forward.
EDS is necessary but not sufficient — cataplexy and CSF orexin decide the subtype.
Clinical history screens for cataplexy episodes next.
Polysomnography and MSLT confirm rapid REM onset.
CSF orexin-A testing finalizes the classification.
Cataplexy is sudden muscle weakness triggered by strong emotion.
Sudden bilateral muscle weakness follows strong emotion.
Jaw sag, head drop, or full body collapse can occur.
Episodes last seconds to a few minutes.
Cataplexy reflects intrusion of REM muscle atonia while awake.
Its presence strongly predicts CSF orexin-A deficiency.
Absence of cataplexy points toward Type 2.
Cataplexy plus low CSF orexin-A together confirm narcolepsy Type 1.
Structured interviews probe emotional triggers carefully.
Video documentation helps confirm atypical presentations.
Misdiagnosis as seizure or syncope is common.
Lumbar puncture measures orexin-A directly from cerebrospinal fluid.
A lumbar puncture collects cerebrospinal fluid for assay.
Radioimmunoassay quantifies orexin-A concentration precisely.
Results classify low, borderline, or normal levels.
Orexin-A level reflects surviving hypothalamic neuron count.
Severe loss produces unmistakably low CSF values.
Mild or no loss keeps values near normal.
CSF orexin-A below 110 pg/mL is essentially diagnostic of Type 1.
Lumbar puncture is invasive and not always available.
Borderline values can occur without clear autoimmune loss.
Results are interpreted alongside cataplexy history.
Cataplexy plus CSF orexin-A below 110 pg/mL defines Type 1.
Orexin-producing neurons are selectively attacked and lost.
Only the lateral hypothalamus population is affected.
Destruction appears irreversible once symptoms emerge.
Cataplexy, sleep paralysis, and hallucinations often co-occur.
Nighttime sleep becomes fragmented and unstable.
Symptoms are usually lifelong and require management.
Type 1 is the clearer, more severe, and better-characterized narcolepsy subtype.
Stimulants address daytime sleepiness symptoms.
Anticataplectic drugs target REM-intrusion pathways.
Orexin receptor agonists are an emerging treatment.
Without cataplexy and with normal CSF orexin-A, Type 2 applies.
Orexin neuron population remains largely intact.
Excessive sleepiness arises through less understood pathways.
Etiology is more heterogeneous than Type 1.
No single biomarker confirms Type 2 conclusively.
MSLT criteria and symptom history carry more weight.
A minority later develop cataplexy and reclassify.
Type 2 is a diagnosis of exclusion built on absence, not a positive biomarker.
Wake-promoting agents remain the primary therapy.
Regular follow-up watches for emerging cataplexy.
Prognosis is generally milder than Type 1.